Drugs / Frespaciguat
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06777602 | Aug → Sep 2022 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT04425733 | Jul → Nov 2020 | COVID-19, pneumonia | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT04370873 | Jun 2020 → Jan 2022 | pulmonary hypertension | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT03744637 | Jan 2019 → Dec 2020 | pulmonary arterial hypertension | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05612035 | Mar 2023 → Apr 2026 overdue | chronic obstructive pulmonary disease, pulmonary hypertension | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT04732221 | May 2021 → Jan 2024 | pulmonary arterial hypertension | Merck Sharp & Dohme LLC | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Frespaciguat | “Frespaciguat (MK-5475), an inhaled soluble guanylate cyclase stimulator, is being studied for its potential to selectively reduce pulmonary vascular pressures with minimal...” PMID 40534306 ↗ Jun 2025 |
| Known as | MK-5475 | “Frespaciguat (MK-5475), an inhaled soluble guanylate cyclase stimulator, is being studied for its potential to selectively reduce pulmonary vascular pressures with minimal...” PMID 40534306 ↗ Jun 20251“Frespaciguat (MK-5475) in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)” NCT04425733 ↗ |
| Action | Activate | “stimulator of soluble guanylate cyclase” PMID 36521262 ↗ Nov 2022 |
| Modality | Small molecule | “an investigational, small-molecule stimulator” PMID 36521262 ↗ Nov 2022 |
| Route | Inhaled | “designed for inhaled delivery via a dry-powder inhaler device” PMID 36521262 ↗ Nov 2022 |